ACTIMMUNE, Phase 3 clinical study will begin enrolling patients in the second quarter of 2015. StreetInsider.com, January 12, 2015
It is anticipated that approximately 110 subjects will be screened at four U.S. centers for eligibility to randomize approximately 90 subjects 1:1 to receive either ACTIMMUNE or placebo. The Company anticipates the study will take 18 months to complete.
Tuesday, January 13, 2015
Subscribe to:
Posts (Atom)
